Even though targeting aberrations that are only altered in a subset of tumour cells can cause clonal selection and drug resistance, targeting EGFR variants can indeed prolong survival in glioblastoma patients, despite tumour recurrence [71]. This evidence concerns the gene EGFR and neoplasm.